{"id":"desloratadine","rwe":[],"_fda":{"id":"7c658c72-2694-49dd-9950-0aed03e3d7dc","set_id":"0fe374d0-c14b-4102-b568-eb79165fc7ef","openfda":{"nui":["N0000000190","N0000175587"],"unii":["FVF865388R"],"route":["ORAL"],"rxcui":["349420"],"spl_id":["7c658c72-2694-49dd-9950-0aed03e3d7dc"],"brand_name":["Desloratadine"],"spl_set_id":["0fe374d0-c14b-4102-b568-eb79165fc7ef"],"package_ndc":["69543-107-30","69543-107-10","69543-107-50"],"product_ndc":["69543-107"],"generic_name":["DESLORATADINE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DESLORATADINE"],"pharm_class_epc":["Histamine-1 Receptor Antagonist [EPC]"],"pharm_class_moa":["Histamine H1 Receptor Antagonists [MoA]"],"manufacturer_name":["Virtus Pharmaceuticals, LLC"],"application_number":["ANDA078355"],"is_original_packager":[true]},"version":"7","pregnancy":["8.1 Pregnancy Risk Summary The limited available data with Desloratadine in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. There are no adequate and well-controlled studies in pregnant women. Desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (AUC)-based exposures of desloratadine and its metabolite approximately 320 times that at the recommended human daily oral dose (RHD) of 5 mg/day. Desloratadine given during organogenesis to pregnant rabbits was not teratogenic at the AUC-based exposures of desloratadine approximately 230 times that at the RHD. Desloratadine given to pregnant rats during organogenesis through lactation resulted in reduced body weight and slow righting reflex of F 1 pups at the summed AUC-based exposures of desloratadine and its metabolite approximately 70 times or greater than that at the RHD [ see Data ]. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Desloratadine was given orally during organogenesis to pregnant rats at doses of 6, 24 and 48 mg/kg/day (approximately 50, 200 and 320 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). No fetal malformations were present. Reduced fetal weights and skeletal variations noted at doses of 24 and 48 mg/kg/day were likely secondary to the maternal toxicities of reduced body weight gain and food consumption observed at the same doses. Desloratadine was also given orally during organogenesis to pregnant rabbits at doses of 15, 30 and 60 mg/kg/day (approximately 30, 70 and 230 times the AUC-based exposure of desloratadine at the RHD). No adverse effects to the fetus were noted. Reduced maternal body weight gain was noted in rabbits at 60 mg/kg/day. In a peri- and post-natal development study, desloratadine was given to rats orally during the perinatal (Gestation Day 6) through lactation periods (Postpartum Day 21) at doses of 3, 9 and 18 mg/kg/day. Reduced body weight and slow righting reflex were reported in F 1 pups at doses of 9 mg/kg/day or greater (approximately 70 times or greater than the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Desloratadine had no effect on F 1 pup development at 3 mg/kg/day (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Maternal toxicities including reduced body weight gain and food consumption were noted at 18 mg/kg/day for F 0 dams. F 1 offspring were subsequently mated and there was no developmental toxicity for F 2 pups observed."],"overdosage":["10 OVERDOSAGE In the event of overdose, consider standard measures to remove any unabsorbed drug. Symptomatic and supportive treatment is recommended. Desloratadine and 3-hydroxydesloratadine are not eliminated by hemodialysis. Information regarding acute overdosage is limited to experience from post-marketing adverse event reports and from clinical trials conducted during the development of the Desloratadine product. In a dose-ranging trial, at doses of 10 mg and 20 mg/day somnolence was reported. In another study, no clinically relevant adverse events were reported in normal male and female volunteers who were given single daily doses of Desloratadine 45 mg for 10 days [ see Clinical Pharmacology (12.2) ]."],"description":["11 DESCRIPTION Desloratadine Tablets are light blue, round, tablets containing 5 mg desloratadine, an antihistamine, to be administered orally. Desloratadine Tablets also contain the following excipients: microcrystalline cellulose NF, pregelatinized starch NF, croscarmellose sodium NF, talc USP, zinc stearate, USP and FD&C Blue #2 HT 11-14%. Desloratadine is a white to off-white powder that is slightly soluble in water, but very soluble in ethanol and propylene glycol. It has an empirical formula: C 19 H 19 ClN 2 and a molecular weight of 310.8. The chemical name is 8-chloro-6,11-dihydro-11-(4-piperdinylidene)-5 H -benzo[5,6]cyclohepta[1,2-b]pyridine and has the following structure: Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Desloratadine Tablets: Debossed \"5\", light blue, round tablets that are packaged in high-density polyethylene plastic bottles of 100 (NDC 69543-107-10) and 500 (NDC 69543-107-50). Storage • Desloratadine Tablets: Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Heat sensitive. Avoid exposure at or above 30°C (86°F). Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure."],"geriatric_use":["8.5 Geriatric Use Clinical studies of desloratadine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. [ See Clinical Pharmacology (12.3) . ]"],"pediatric_use":["8.4 Pediatric Use The recommended dose of Desloratadine Oral Solution in the pediatric population is based on cross-study comparison of the plasma concentration of Desloratadine in adults and pediatric subjects. The safety of Desloratadine Oral Solution has been established in 246 pediatric subjects aged 6 months to 11 years in three placebo-controlled clinical studies. Since the course of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria and the effects of Desloratadine are sufficiently similar in the pediatric and adult populations, it allows extrapolation from the adult efficacy data to pediatric patients. The effectiveness of Desloratadine Oral Solution in these age groups is supported by evidence from adequate and well-controlled studies of Desloratadine Tablets in adults. The safety and effectiveness of Desloratadine Tablets or Desloratadine Oral Solution have not been demonstrated in pediatric patients less than 6 months of age. [ See Clinical Pharmacology (12.3) . ]"],"effective_time":"20250710","clinical_studies":["14 CLINICAL STUDIES 14.1 Seasonal Allergic Rhinitis The clinical efficacy and safety of Desloratadine Tablets were evaluated in over 2300 patients 12 to 75 years of age with seasonal allergic rhinitis. A total of 1838 patients received 2.5 to 20 mg/day of Desloratadine in 4 double-blind, randomized, placebo-controlled clinical trials of 2 to 4 weeks' duration conducted in the United States. The results of these studies demonstrated the efficacy and safety of Desloratadine 5 mg in the treatment of adult and adolescent patients with seasonal allergic rhinitis. In a dose-ranging trial, Desloratadine 2.5 to 20 mg/day was studied. Doses of 5, 7.5, 10, and 20 mg/day were superior to placebo; and no additional benefit was seen at doses above 5.0 mg. In the same study, an increase in the incidence of somnolence was observed at doses of 10 mg/day and 20 mg/day (5.2% and 7.6%, respectively), compared to placebo (2.3%). In two 4-week studies of 924 patients (aged 15 to 75 years) with seasonal allergic rhinitis and concomitant asthma, Desloratadine Tablets 5 mg once daily improved rhinitis symptoms, with no decrease in pulmonary function. This supports the safety of administering Desloratadine Tablets to adult patients with seasonal allergic rhinitis with mild to moderate asthma. Desloratadine Tablets 5 mg once daily significantly reduced the Total Symptom Score (the sum of individual scores of nasal and non-nasal symptoms) in patients with seasonal allergic rhinitis. See Table 3 . Table 3 TOTAL SYMPTOM SCORE (TSS) Changes in a 2 Week Clinical Trial in Patients with Seasonal Allergic Rhinitis Treatment Group (n) Mean Baseline At baseline, a total nasal symptom score (sum of 4 individual symptoms) of at least 6 and a total non-nasal symptom score (sum of 4 individual symptoms) of at least 5 (each symptom scored 0 to 3 where 0=no symptom and 3=severe symptoms) was required for trial eligibility. TSS ranges from 0=no symptoms to 24=maximal symptoms. (SEM) Change from Baseline Mean reduction in TSS averaged over the 2-week treatment period. (SEM) Placebo Comparison ( P -value) SEM = Standard Error of the Mean Desloratadine 5.0 mg (171) 14.2 (0.3) -4.3 (0.3) P <0.01 Placebo (173) 13.7 (0.3) -2.5 (0.3) There were no significant differences in the effectiveness of Desloratadine Tablets 5 mg across subgroups of patients defined by gender, age, or race. 14.2 Perennial Allergic Rhinitis The clinical efficacy and safety of Desloratadine Tablets 5 mg were evaluated in over 1300 patients 12 to 80 years of age with perennial allergic rhinitis. A total of 685 patients received 5 mg/day of Desloratadine in two double-blind, randomized, placebo-controlled clinical trials of 4 weeks' duration conducted in the United States and internationally. In one of these studies Desloratadine Tablets 5 mg once daily was shown to significantly reduce the Total Symptom Score in patients with perennial allergic rhinitis (Table 4). Table 4 TOTAL SYMPTOM SCORE (TSS) Changes in a 4 Week Clinical Trial in Patients with Perennial Allergic Rhinitis Treatment Group (n) Mean Baseline At baseline, average of total symptom score (sum of 5 individual nasal symptoms and 3 non-nasal symptoms, each symptom scored 0 to 3 where 0=no symptom and 3=severe symptoms) of at least 10 was required for trial eligibility. TSS ranges from 0=no symptoms to 24=maximal symptoms. (SEM) Change from Baseline Mean reduction in TSS averaged over the 4 week treatment period. (SEM) Placebo Comparison ( P -value) SEM = Standard Error of the Mean Desloratadine 5.0 mg (337) 12.37 (0.18) -4.06 (0.21) P =0.01 Placebo (337) 12.30 (0.18) -3.27 (0.21) 14.3 Chronic Idiopathic Urticaria The efficacy and safety of Desloratadine Tablets 5 mg once daily was studied in 416 chronic idiopathic urticaria patients 12 to 84 years of age, of whom 211 received Desloratadine. In two double-blind, placebo-controlled, randomized clinical trials of six weeks duration, at the pre-specified one-week primary time point evaluation, Desloratadine Tablets significantly reduced the severity of pruritus when compared to placebo (Table 5). Secondary endpoints were also evaluated, and during the first week of therapy Desloratadine Tablets 5 mg reduced the secondary endpoints, \"Number of Hives\" and the \"Size of the Largest Hive,\" when compared to placebo. Table 5 PRURITUS SYMPTOM SCORE Changes in the First Week of a Clinical Trial in Patients with Chronic Idiopathic Urticaria Treatment Group (n) Mean Baseline (SEM) Change from Baseline Mean reduction in pruritus averaged over the first week of treatment. (SEM) Placebo Comparison ( P -value) Pruritus scored 0 to 3 where 0=no symptom to 3=maximal symptom SEM = Standard Error of the Mean Desloratadine 5.0 mg (115) 2.19 (0.04) -1.05 (0.07) P <0.01 Placebo (110) 2.21 (0.04) -0.52 (0.07)"],"pharmacodynamics":["12.2 Pharmacodynamics Wheal and Flare: Human histamine skin wheal studies following single and repeated 5-mg doses of desloratadine have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal tachyphylaxis within the desloratadine 5-mg group over the 28-day treatment period. The clinical relevance of histamine wheal skin testing is unknown. Effects on QTc: Single daily doses of 45 mg were given to normal male and female volunteers for 10 days. All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In Desloratadine-treated subjects, there was an increase in mean heart rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate (QTc) by both the Bazett and Fridericia methods. Using the QTc (Bazett) there was a mean increase of 8.1 msec in Desloratadine-treated subjects relative to placebo. Using QTc (Fridericia) there was a mean increase of 0.4 msec in Desloratadine-treated subjects relative to placebo. No clinically relevant adverse events were reported."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively. Neither food nor grapefruit juice had an effect on the bioavailability (C max and AUC) of desloratadine. The pharmacokinetic profile of Desloratadine Oral Solution was evaluated in a three-way crossover study in 30 adult volunteers. A single dose of 10 mL of Desloratadine Oral Solution containing 5 mg of desloratadine was bioequivalent to a single dose of 5 mg Desloratadine Tablet. Food had no effect on the bioavailability (AUC and C max ) of Desloratadine Oral Solution. Distribution Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89% bound to plasma proteins, respectively. Protein binding of desloratadine and 3-hydroxydesloratadine was unaltered in subjects with impaired renal function. Metabolism Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. The enzyme(s) responsible for the formation of 3-hydroxydesloratadine have not been identified. Data from clinical trials indicate that a subset of the general population has a decreased ability to form 3-hydroxydesloratadine, and are poor metabolizers of desloratadine. In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours). These pharmacokinetic studies included subjects between the ages of 2 and 70 years, including 977 subjects aged 2 to 5 years, 1575 subjects aged 6 to 11 years, and 1196 subjects aged 12 to 70 years. There was no difference in the prevalence of poor metabolizers across age groups. The frequency of poor metabolizers was higher in Blacks (17%, n=988) as compared to Caucasians (2%, n=1,462) and Hispanics (2%, n=1,063). The median exposure (AUC) to desloratadine in the poor metabolizers was approximately 6-fold greater than in the subjects who are not poor metabolizers. Subjects who are poor metabolizers of desloratadine cannot be prospectively identified and will be exposed to higher levels of desloratadine following dosing with the recommended dose of desloratadine. In multidose clinical safety studies, where metabolizer status was identified, a total of 94 poor metabolizers and 123 normal metabolizers were enrolled and treated with Desloratadine Oral Solution for 15-35 days. In these studies, no overall differences in safety were observed between poor metabolizers and normal metabolizers. Although not seen in these studies, an increased risk of exposure-related adverse events in patients who are poor metabolizers cannot be ruled out. Elimination The mean plasma elimination half-life of desloratadine was approximately 27 hours. C max and AUC values increased in a dose proportional manner following single oral doses between 5 and 20 mg. The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency. A human mass balance study documented a recovery of approximately 87% of the 14C-desloratadine dose, which was equally distributed in urine and feces as metabolic products. Analysis of plasma 3-hydroxydesloratadine showed similar T max and half-life values compared to desloratadine. Special Populations Geriatric Subjects: In older subjects (≥65 years old; n=17) following multiple-dose administration of Desloratadine Tablets, the mean C max and AUC values for desloratadine were 20% greater than in younger subjects (<65 years old). The oral total body clearance (CL/F) when normalized for body weight was similar between the two age groups. The mean plasma elimination half-life of desloratadine was 33.7 hr in subjects ≥65 years old. The pharmacokinetics for 3-hydroxydesloratadine appeared unchanged in older versus younger subjects. These age-related differences are unlikely to be clinically relevant and no dosage adjustment is recommended in elderly subjects. Pediatric Subjects: In subjects 6 to 11 years old, a single dose of 5 mL of Desloratadine Oral solution containing 2.5 mg of desloratadine, resulted in desloratadine plasma concentrations similar to those achieved in adults administered a single 5-mg Desloratadine Tablet. In subjects 2 to 5 years old, a single dose of 2.5 mL of Desloratadine Oral solution containing 1.25 mg of desloratadine, resulted in desloratadine plasma concentrations similar to those achieved in adults administered a single 5-mg Desloratadine Tablet. However, the C max and AUC of the metabolite (3-hydroxydesloratadine) were 1.27 and 1.61 times higher for the 5-mg dose of Oral solution administered in adults compared to the C max and AUC obtained in children 2 to 11 years of age receiving 1.25-2.5 mg of Desloratadine Oral solution. A single dose of either 2.5 mL or 1.25 mL of Desloratadine Oral solution containing 1.25 mg or 0.625 mg, respectively, of desloratadine was administered to subjects 6 to 11 months of age and 12 to 23 months of age. The results of a population pharmacokinetic analysis indicated that a dose of 1 mg for subjects aged 6 to 11 months and 1.25 mg for subjects 12 to 23 months of age is required to obtain desloratadine plasma concentrations similar to those achieved in adults administered a single 5-mg dose of Desloratadine Oral solution. Renally Impaired: Desloratadine pharmacokinetics following a single dose of 7.5 mg were characterized in patients with mild (n=7; creatinine clearance 51-69 mL/min/1.73 m 2 ), moderate (n=6; creatinine clearance 34-43 mL/min/1.73 m 2 ), and severe (n=6; creatinine clearance 5-29 mL/min/1.73 m 2 ) renal impairment or hemodialysis dependent (n=6) patients. In patients with mild and moderate renal impairment, median C max and AUC values increased by approximately 1.2- and 1.9-fold, respectively, relative to subjects with normal renal function. In patients with severe renal impairment or who were hemodialysis dependent, C max and AUC values increased by approximately 1.7- and 2.5-fold, respectively. Minimal changes in 3-hydroxydesloratadine concentrations were observed. Desloratadine and 3-hydroxydesloratadine were poorly removed by hemodialysis. Plasma protein binding of desloratadine and 3-hydroxydesloratadine was unaltered by renal impairment. Dosage adjustment for patients with renal impairment is recommended [ see Dosage and Administration (2.5) ]. Hepatically Impaired: Desloratadine pharmacokinetics were characterized following a single oral dose in patients with mild (n=4), moderate (n=4), and severe (n=4) hepatic impairment as defined by the Child-Pugh classification of hepatic function and 8 subjects with normal hepatic function. Patients with hepatic impairment, regardless of severity, had approximately a 2.4-fold increase in AUC as compared with normal subjects. The apparent oral clearance of desloratadine in patients with mild, moderate, and severe hepatic impairment was 37%, 36%, and 28% of that in normal subjects, respectively. An increase in the mean elimination half-life of desloratadine in patients with hepatic impairment was observed. For 3-hydroxydesloratadine, the mean C max and AUC values for patients with hepatic impairment were not statistically significantly different from subjects with normal hepatic function. Dosage adjustment for patients with hepatic impairment is recommended [ see Dosage and Administration (2.5) ]. Gender: Female subjects treated for 14 days with Desloratadine Tablets had 10% and 3% higher desloratadine C max and AUC values, respectively, compared with male subjects. The 3-hydroxydesloratadine C max and AUC values were also increased by 45% and 48%, respectively, in females compared with males. However, these apparent differences are not likely to be clinically relevant and therefore no dosage adjustment is recommended. Race: Following 14 days of treatment with Desloratadine Tablets, the C max and AUC values for desloratadine were 18% and 32% higher, respectively, in Blacks compared with Caucasians. For 3-hydroxydesloratadine there was a corresponding 10% reduction in C max and AUC values in Blacks compared to Caucasians. These differences are not likely to be clinically relevant and therefore no dose adjustment is recommended. Drug Interactions: In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) and female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days. In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23-day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady-state conditions to normal healthy male and female volunteers. Although increased plasma concentrations (C max and AUC 0-24 hrs ) of desloratadine and 3-hydroxydesloratadine were observed (see Table 2 ), there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events. Table 2 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers Desloratadine 3-Hydroxydesloratadine C max AUC 0-24 hrs C max AUC 0-24 hrs Erythromycin (500 mg Q8h) +24% +14% +43% +40% Ketoconazole (200 mg Q12h) +45% +39% +43% +72% Azithromycin (500 mg day 1, 250 mg QD × 4 days) +15% +5% +15% +4% Fluoxetine (20 mg QD) +15% +0% +17% +13% Cimetidine (600 mg Q12h) +12% +19% -11% -3%"],"adverse_reactions":["6 ADVERSE REACTIONS The following adverse reactions are discussed in greater detail in other sections of the label: • Hypersensitivity reactions. [ See Warnings and Precautions (5.1) .] • The most common adverse reactions (reported in ≥2% of adult and adolescent patients with allergic rhinitis and greater than placebo) were pharyngitis, dry mouth, myalgia, fatigue, somnolence, dysmenorrhea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Virtus Pharmaceuticals, LLC at 1-888-848-3593 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adults and Adolescents Allergic Rhinitis: In multiple-dose placebo-controlled trials, 2834 patients ages 12 years or older received Desloratadine Tablets at doses of 2.5 mg to 20 mg daily, of whom 1655 patients received the recommended daily dose of 5 mg. In patients receiving 5 mg daily, the rate of adverse events was similar between Desloratadine and placebo-treated patients. The percent of patients who withdrew prematurely due to adverse events was 2.4% in the Desloratadine group and 2.6% in the placebo group. There were no serious adverse events in these trials in patients receiving desloratadine. All adverse events that were reported by greater than or equal to 2% of patients who received the recommended daily dose of Desloratadine Tablets (5 mg once daily), and that were more common with Desloratadine Tablets than placebo, are listed in Table 1. Table 1 Incidence of Adverse Events Reported by ≥2% of Adult and Adolescent Allergic Rhinitis Patients Receiving Desloratadine Tablets Adverse Event Desloratadine Tablets 5 mg (n=1655) Placebo (n=1652) Infections and Infestations Pharyngitis 4.1% 2.0% Nervous System Disorders Somnolence 2.1% 1.8% Gastrointestinal Disorders Dry Mouth 3.0% 1.9% Musculoskeletal and Connective Tissue Disorders Myalgia 2.1% 1.8% Reproductive System and Breast Disorders Dysmenorrhea 2.1% 1.6% General Disorders and Administration Site Conditions Fatigue 2.1% 1.2% The frequency and magnitude of laboratory and electrocardiographic abnormalities were similar in Desloratadine and placebo-treated patients. There were no differences in adverse events for subgroups of patients as defined by gender, age, or race. Chronic Idiopathic Urticaria: In multiple-dose, placebo-controlled trials of chronic idiopathic urticaria, 211 patients ages 12 years or older received Desloratadine Tablets and 205 received placebo. Adverse events that were reported by greater than or equal to 2% of patients who received Desloratadine Tablets and that were more common with Desloratadine than placebo were (rates for Desloratadine and placebo, respectively): headache (14%, 13%), nausea (5%, 2%), fatigue (5%, 1%), dizziness (4%, 3%), pharyngitis (3%, 2%), dyspepsia (3%, 1%), and myalgia (3%, 1%). Pediatrics Two hundred and forty-six pediatric subjects 6 months to 11 years of age received Desloratadine Oral Solution for 15 days in three placebo-controlled clinical trials. Pediatric subjects aged 6 to 11 years received 2.5 mg once a day, subjects aged 1 to 5 years received 1.25 mg once a day, and subjects 6 to 11 months of age received 1.0 mg once a day. In subjects 6 to 11 years of age, no individual adverse event was reported by 2 percent or more of the subjects. In subjects 2 to 5 years of age, adverse events reported for Desloratadine and placebo in at least 2 percent of subjects receiving Desloratadine Oral Solution and at a frequency greater than placebo were fever (5.5%, 5.4%), urinary tract infection (3.6%, 0%) and varicella (3.6%, 0%). In subjects 12 months to 23 months of age, adverse events reported for the Desloratadine product and placebo in at least 2 percent of subjects receiving Desloratadine Oral Solution and at a frequency greater than placebo were fever (16.9%, 12.9%), diarrhea (15.4%, 11.3%), upper respiratory tract infections (10.8%, 9.7%), coughing (10.8%, 6.5%), appetite increased (3.1%, 1.6%), emotional lability (3.1%, 0%), epistaxis (3.1%, 0%), parasitic infection (3.1%, 0%), pharyngitis (3.1%, 0%), rash maculopapular (3.1%, 0%). In subjects 6 months to 11 months of age, adverse events reported for Desloratadine and placebo in at least 2 percent of subjects receiving Desloratadine Oral Solution and at a frequency greater than placebo were upper respiratory tract infections (21.2%, 12.9%), diarrhea (19.7%, 8.1%), fever (12.1%, 1.6%), irritability (12.1%, 11.3%), coughing (10.6%, 9.7%), somnolence (9.1%, 8.1%), bronchitis (6.1%, 0%), otitis media (6.1%, 1.6%), vomiting (6.1%, 3.2%), anorexia (4.5%, 1.6%), pharyngitis (4.5%, 1.6%), insomnia (4.5%, 0%), rhinorrhea (4.5%, 3.2%), erythema (3.0%, 1.6%), and nausea (3.0%, 0%). There were no clinically meaningful changes in any electrocardiographic parameter, including the QTc interval. Only one of the 246 pediatric subjects receiving Desloratadine Oral Solution in the clinical trials discontinued treatment because of an adverse event. 6.2 Post-Marketing Experience Because adverse events are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following spontaneous adverse events have been reported during the marketing of desloratadine: Cardiac disorders: tachycardia, palpitations Respiratory, thoracic and mediastinal disorders: dyspnea Skin and subcutaneous tissue disorders: rash, pruritus Nervous system disorders: psychomotor hyperactivity, movement disorders (including dystonia, tics, and extrapyramidal symptoms), seizures (reported in patients with and without a known seizure disorder) Immune system disorders: hypersensitivity reactions (such as urticaria, edema and anaphylaxis) Investigations: elevated liver enzymes including bilirubin Hepatobiliary disorders: hepatitis Metabolism and nutrition disorders: increased appetite"],"contraindications":["4 CONTRAINDICATIONS Desloratadine Tablets are contraindicated in patients who are hypersensitive to this medication or to any of its ingredients or to loratadine [ see Warnings and Precautions (5.1) and Adverse Reactions (6.2) ]. • Hypersensitivity ( 4 , 6.2 )"],"drug_interactions":["7 DRUG INTERACTIONS 7.1 Inhibitors of Cytochrome P450 3A4 In controlled clinical studies co-administration of desloratadine with ketoconazole, erythromycin, or azithromycin resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [ See Clinical Pharmacology (12.3) .] 7.2 Fluoxetine In controlled clinical studies co-administration of desloratadine with fluoxetine, a selective serotonin reuptake inhibitor (SSRI), resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [ See Clinical Pharmacology (12.3) .] 7.3 Cimetidine In controlled clinical studies co-administration of desloratadine with cimetidine, a histamine H 2 -receptor antagonist, resulted in increased plasma concentrations of desloratadine and 3 hydroxydesloratadine, but there were no clinically relevant changes in the safety profile of desloratadine. [ See Clinical Pharmacology (12.3) . ]"],"mechanism_of_action":["12.1 Mechanism of Action Desloratadine is a long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2-3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this finding is unknown."],"storage_and_handling":["Storage • Desloratadine Tablets: Store at 25°C (77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Heat sensitive. Avoid exposure at or above 30°C (86°F). Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Desloratadine is a long-acting tricyclic histamine antagonist with selective H 1 -receptor histamine antagonist activity. Receptor binding data indicates that at a concentration of 2-3 ng/mL (7 nanomolar), desloratadine shows significant interaction with the human histamine H 1 -receptor. Desloratadine inhibited histamine release from human mast cells in vitro . Results of a radiolabeled tissue distribution study in rats and a radioligand H 1 -receptor binding study in guinea pigs showed that desloratadine did not readily cross the blood brain barrier. The clinical significance of this finding is unknown. 12.2 Pharmacodynamics Wheal and Flare: Human histamine skin wheal studies following single and repeated 5-mg doses of desloratadine have shown that the drug exhibits an antihistaminic effect by 1 hour; this activity may persist for as long as 24 hours. There was no evidence of histamine-induced skin wheal tachyphylaxis within the desloratadine 5-mg group over the 28-day treatment period. The clinical relevance of histamine wheal skin testing is unknown. Effects on QTc: Single daily doses of 45 mg were given to normal male and female volunteers for 10 days. All ECGs obtained in this study were manually read in a blinded fashion by a cardiologist. In Desloratadine-treated subjects, there was an increase in mean heart rate of 9.2 bpm relative to placebo. The QT interval was corrected for heart rate (QTc) by both the Bazett and Fridericia methods. Using the QTc (Bazett) there was a mean increase of 8.1 msec in Desloratadine-treated subjects relative to placebo. Using QTc (Fridericia) there was a mean increase of 0.4 msec in Desloratadine-treated subjects relative to placebo. No clinically relevant adverse events were reported. 12.3 Pharmacokinetics Absorption Following oral administration of a desloratadine 5 mg tablet once daily for 10 days to normal healthy volunteers, the mean time to maximum plasma concentrations (T max ) occurred at approximately 3 hours post dose and mean steady state peak plasma concentrations (C max ) and AUC of 4 ng/mL and 56.9 ng∙hr/mL were observed, respectively. Neither food nor grapefruit juice had an effect on the bioavailability (C max and AUC) of desloratadine. The pharmacokinetic profile of Desloratadine Oral Solution was evaluated in a three-way crossover study in 30 adult volunteers. A single dose of 10 mL of Desloratadine Oral Solution containing 5 mg of desloratadine was bioequivalent to a single dose of 5 mg Desloratadine Tablet. Food had no effect on the bioavailability (AUC and C max ) of Desloratadine Oral Solution. Distribution Desloratadine and 3-hydroxydesloratadine are approximately 82% to 87% and 85% to 89% bound to plasma proteins, respectively. Protein binding of desloratadine and 3-hydroxydesloratadine was unaltered in subjects with impaired renal function. Metabolism Desloratadine (a major metabolite of loratadine) is extensively metabolized to 3-hydroxydesloratadine, an active metabolite, which is subsequently glucuronidated. The enzyme(s) responsible for the formation of 3-hydroxydesloratadine have not been identified. Data from clinical trials indicate that a subset of the general population has a decreased ability to form 3-hydroxydesloratadine, and are poor metabolizers of desloratadine. In pharmacokinetic studies (n=3748), approximately 6% of subjects were poor metabolizers of desloratadine (defined as a subject with an AUC ratio of 3-hydroxydesloratadine to desloratadine less than 0.1, or a subject with a desloratadine half-life exceeding 50 hours). These pharmacokinetic studies included subjects between the ages of 2 and 70 years, including 977 subjects aged 2 to 5 years, 1575 subjects aged 6 to 11 years, and 1196 subjects aged 12 to 70 years. There was no difference in the prevalence of poor metabolizers across age groups. The frequency of poor metabolizers was higher in Blacks (17%, n=988) as compared to Caucasians (2%, n=1,462) and Hispanics (2%, n=1,063). The median exposure (AUC) to desloratadine in the poor metabolizers was approximately 6-fold greater than in the subjects who are not poor metabolizers. Subjects who are poor metabolizers of desloratadine cannot be prospectively identified and will be exposed to higher levels of desloratadine following dosing with the recommended dose of desloratadine. In multidose clinical safety studies, where metabolizer status was identified, a total of 94 poor metabolizers and 123 normal metabolizers were enrolled and treated with Desloratadine Oral Solution for 15-35 days. In these studies, no overall differences in safety were observed between poor metabolizers and normal metabolizers. Although not seen in these studies, an increased risk of exposure-related adverse events in patients who are poor metabolizers cannot be ruled out. Elimination The mean plasma elimination half-life of desloratadine was approximately 27 hours. C max and AUC values increased in a dose proportional manner following single oral doses between 5 and 20 mg. The degree of accumulation after 14 days of dosing was consistent with the half-life and dosing frequency. A human mass balance study documented a recovery of approximately 87% of the 14C-desloratadine dose, which was equally distributed in urine and feces as metabolic products. Analysis of plasma 3-hydroxydesloratadine showed similar T max and half-life values compared to desloratadine. Special Populations Geriatric Subjects: In older subjects (≥65 years old; n=17) following multiple-dose administration of Desloratadine Tablets, the mean C max and AUC values for desloratadine were 20% greater than in younger subjects (<65 years old). The oral total body clearance (CL/F) when normalized for body weight was similar between the two age groups. The mean plasma elimination half-life of desloratadine was 33.7 hr in subjects ≥65 years old. The pharmacokinetics for 3-hydroxydesloratadine appeared unchanged in older versus younger subjects. These age-related differences are unlikely to be clinically relevant and no dosage adjustment is recommended in elderly subjects. Pediatric Subjects: In subjects 6 to 11 years old, a single dose of 5 mL of Desloratadine Oral solution containing 2.5 mg of desloratadine, resulted in desloratadine plasma concentrations similar to those achieved in adults administered a single 5-mg Desloratadine Tablet. In subjects 2 to 5 years old, a single dose of 2.5 mL of Desloratadine Oral solution containing 1.25 mg of desloratadine, resulted in desloratadine plasma concentrations similar to those achieved in adults administered a single 5-mg Desloratadine Tablet. However, the C max and AUC of the metabolite (3-hydroxydesloratadine) were 1.27 and 1.61 times higher for the 5-mg dose of Oral solution administered in adults compared to the C max and AUC obtained in children 2 to 11 years of age receiving 1.25-2.5 mg of Desloratadine Oral solution. A single dose of either 2.5 mL or 1.25 mL of Desloratadine Oral solution containing 1.25 mg or 0.625 mg, respectively, of desloratadine was administered to subjects 6 to 11 months of age and 12 to 23 months of age. The results of a population pharmacokinetic analysis indicated that a dose of 1 mg for subjects aged 6 to 11 months and 1.25 mg for subjects 12 to 23 months of age is required to obtain desloratadine plasma concentrations similar to those achieved in adults administered a single 5-mg dose of Desloratadine Oral solution. Renally Impaired: Desloratadine pharmacokinetics following a single dose of 7.5 mg were characterized in patients with mild (n=7; creatinine clearance 51-69 mL/min/1.73 m 2 ), moderate (n=6; creatinine clearance 34-43 mL/min/1.73 m 2 ), and severe (n=6; creatinine clearance 5-29 mL/min/1.73 m 2 ) renal impairment or hemodialysis dependent (n=6) patients. In patients with mild and moderate renal impairment, median C max and AUC values increased by approximately 1.2- and 1.9-fold, respectively, relative to subjects with normal renal function. In patients with severe renal impairment or who were hemodialysis dependent, C max and AUC values increased by approximately 1.7- and 2.5-fold, respectively. Minimal changes in 3-hydroxydesloratadine concentrations were observed. Desloratadine and 3-hydroxydesloratadine were poorly removed by hemodialysis. Plasma protein binding of desloratadine and 3-hydroxydesloratadine was unaltered by renal impairment. Dosage adjustment for patients with renal impairment is recommended [ see Dosage and Administration (2.5) ]. Hepatically Impaired: Desloratadine pharmacokinetics were characterized following a single oral dose in patients with mild (n=4), moderate (n=4), and severe (n=4) hepatic impairment as defined by the Child-Pugh classification of hepatic function and 8 subjects with normal hepatic function. Patients with hepatic impairment, regardless of severity, had approximately a 2.4-fold increase in AUC as compared with normal subjects. The apparent oral clearance of desloratadine in patients with mild, moderate, and severe hepatic impairment was 37%, 36%, and 28% of that in normal subjects, respectively. An increase in the mean elimination half-life of desloratadine in patients with hepatic impairment was observed. For 3-hydroxydesloratadine, the mean C max and AUC values for patients with hepatic impairment were not statistically significantly different from subjects with normal hepatic function. Dosage adjustment for patients with hepatic impairment is recommended [ see Dosage and Administration (2.5) ]. Gender: Female subjects treated for 14 days with Desloratadine Tablets had 10% and 3% higher desloratadine C max and AUC values, respectively, compared with male subjects. The 3-hydroxydesloratadine C max and AUC values were also increased by 45% and 48%, respectively, in females compared with males. However, these apparent differences are not likely to be clinically relevant and therefore no dosage adjustment is recommended. Race: Following 14 days of treatment with Desloratadine Tablets, the C max and AUC values for desloratadine were 18% and 32% higher, respectively, in Blacks compared with Caucasians. For 3-hydroxydesloratadine there was a corresponding 10% reduction in C max and AUC values in Blacks compared to Caucasians. These differences are not likely to be clinically relevant and therefore no dose adjustment is recommended. Drug Interactions: In two controlled crossover clinical pharmacology studies in healthy male (n=12 in each study) and female (n=12 in each study) volunteers, desloratadine 7.5 mg (1.5 times the daily dose) once daily was coadministered with erythromycin 500 mg every 8 hours or ketoconazole 200 mg every 12 hours for 10 days. In three separate controlled, parallel group clinical pharmacology studies, desloratadine at the clinical dose of 5 mg has been coadministered with azithromycin 500 mg followed by 250 mg once daily for 4 days (n=18) or with fluoxetine 20 mg once daily for 7 days after a 23-day pretreatment period with fluoxetine (n=18) or with cimetidine 600 mg every 12 hours for 14 days (n=18) under steady-state conditions to normal healthy male and female volunteers. Although increased plasma concentrations (C max and AUC 0-24 hrs ) of desloratadine and 3-hydroxydesloratadine were observed (see Table 2 ), there were no clinically relevant changes in the safety profile of desloratadine, as assessed by electrocardiographic parameters (including the corrected QT interval), clinical laboratory tests, vital signs, and adverse events. Table 2 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers Desloratadine 3-Hydroxydesloratadine C max AUC 0-24 hrs C max AUC 0-24 hrs Erythromycin (500 mg Q8h) +24% +14% +43% +40% Ketoconazole (200 mg Q12h) +45% +39% +43% +72% Azithromycin (500 mg day 1, 250 mg QD × 4 days) +15% +5% +15% +4% Fluoxetine (20 mg QD) +15% +0% +17% +13% Cimetidine (600 mg Q12h) +12% +19% -11% -3%"],"indications_and_usage":["1 INDICATIONS AND USAGE Desloratadine Tablets are a histamine-1 (H1) receptor antagonist indicated for: • Seasonal Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 12 years of age and older. ( 1.1 ) • Perennial Allergic Rhinitis: relief of nasal and non-nasal symptoms in patients 12 years of age and older. ( 1.2 ) • Chronic Idiopathic Urticaria: symptomatic relief of pruritus, reduction in the number of hives, and size of hives in patients 12 years of age and older. ( 1.3 ) 1.1 Seasonal Allergic Rhinitis Desloratadine Tablets are indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis in patients 12 years of age and older. 1.2 Perennial Allergic Rhinitis Desloratadine Tablets are indicated for the relief of the nasal and non-nasal symptoms of perennial allergic rhinitis in patients 12 years of age and older. 1.3 Chronic Idiopathic Urticaria Desloratadine Tablets are indicated for the symptomatic relief of pruritus, reduction in the number of hives, and size of hives, in patients with chronic idiopathic urticaria 12 years of age and older."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS • Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported. In such cases, stop Desloratadine Tablets at once and consider alternative treatments. ( 5.1 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions including rash, pruritus, urticaria, edema, dyspnea, and anaphylaxis have been reported after administration of desloratadine. If such a reaction occurs, therapy with Desloratadine Tablets should be stopped and alternative treatment should be considered. [ See Adverse Reactions (6.2) .]"],"clinical_studies_table":["
Table 3 TOTAL SYMPTOM SCORE (TSS) Changes in a 2 Week Clinical Trial in Patients with Seasonal Allergic Rhinitis
Treatment Group (n)Mean BaselineAt baseline, a total nasal symptom score (sum of 4 individual symptoms) of at least 6 and a total non-nasal symptom score (sum of 4 individual symptoms) of at least 5 (each symptom scored 0 to 3 where 0=no symptom and 3=severe symptoms) was required for trial eligibility. TSS ranges from 0=no symptoms to 24=maximal symptoms. (SEM)Change from BaselineMean reduction in TSS averaged over the 2-week treatment period. (SEM)Placebo Comparison (P-value)
SEM = Standard Error of the Mean
Desloratadine 5.0 mg (171)14.2 (0.3)-4.3 (0.3)P<0.01
Placebo (173)13.7 (0.3)-2.5 (0.3)
","
Table 4 TOTAL SYMPTOM SCORE (TSS) Changes in a 4 Week Clinical Trial in Patients with Perennial Allergic Rhinitis
Treatment Group (n)Mean BaselineAt baseline, average of total symptom score (sum of 5 individual nasal symptoms and 3 non-nasal symptoms, each symptom scored 0 to 3 where 0=no symptom and 3=severe symptoms) of at least 10 was required for trial eligibility. TSS ranges from 0=no symptoms to 24=maximal symptoms. (SEM)Change from BaselineMean reduction in TSS averaged over the 4 week treatment period. (SEM)Placebo Comparison (P-value)
SEM = Standard Error of the Mean
Desloratadine 5.0 mg (337)12.37 (0.18)-4.06 (0.21)P=0.01
Placebo (337)12.30 (0.18)-3.27 (0.21)
","
Table 5 PRURITUS SYMPTOM SCORE Changes in the First Week of a Clinical Trial in Patients with Chronic Idiopathic Urticaria
Treatment Group (n)Mean Baseline (SEM)Change from BaselineMean reduction in pruritus averaged over the first week of treatment. (SEM)Placebo Comparison (P-value)
Pruritus scored 0 to 3 where 0=no symptom to 3=maximal symptom
SEM = Standard Error of the Mean
Desloratadine 5.0 mg (115)2.19 (0.04)-1.05 (0.07)P<0.01
Placebo (110)2.21 (0.04)-0.52 (0.07)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity Studies The carcinogenic potential of desloratadine was assessed using a loratadine study in rats and a desloratadine study in mice. In a 2-year study in rats, loratadine was administered in the diet at doses up to 25 mg/kg/day (approximately 45 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). A significantly higher incidence of hepatocellular tumors (combined adenomas and carcinomas) was observed in males given 10 mg/kg/day of loratadine (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD) and in males and females given 25 mg/kg/day of loratadine. The clinical significance of these findings during long-term use of desloratadine is not known. In a 2-year dietary study in mice, males and females given up to 16 mg/kg/day and 32 mg/kg/day desloratadine, respectively (approximately 30 and 70 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD, respectively), did not show significant increases in the incidence of any tumors. Genotoxicity Studies In genotoxicity studies with desloratadine, there was no evidence of genotoxic potential in a reverse mutation assay ( Salmonella/E. coli mammalian microsome bacterial mutagenicity assay) or in 2 assays for chromosomal aberrations (human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow micronucleus assay). Impairment of Fertility In a female fertility study, desloratadine was given to female rats orally 14 days prior to and throughout mating until Gestation Day 7 at doses of 6, 12 and 24 mg/kg/day. An increase in preimplantation loss and a decrease in number of implantations and fetuses noted at 24 mg/kg (approximately 200 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD) was likely due to maternal toxicities including reduced body weight gain and food consumption. In a male fertility study in rats, desloratadine was given orally to male rats for 70 days prior to mating and throughout the mating period (total dosing period 106-108 days) at doses of 3, 12 and 40 mg/kg/day. Reduced body weight gain, food consumption, and absolute organ weights of testes, epididymis, and cauda epididymis were noted at 40 mg/kg/day. A male-specific decrease in fertility, demonstrated by reduced female conception rates, decreased sperm numbers and motility, and histopathologic changes in testes and epididymis, occurred at a dose of 12 mg/kg or greater (approximately 65 times or greater than the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Desloratadine had no effect on male fertility in rats at 3 mg/kg/day (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD)."],"pharmacokinetics_table":["
Table 2 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers
Desloratadine3-Hydroxydesloratadine
CmaxAUC0-24 hrsCmaxAUC0-24 hrs
Erythromycin (500 mg Q8h)+24%+14%+43%+40%
Ketoconazole (200 mg Q12h)+45%+39%+43%+72%
Azithromycin (500 mg day 1, 250 mg QD × 4 days)+15%+5%+15%+4%
Fluoxetine (20 mg QD)+15%+0%+17%+13%
Cimetidine (600 mg Q12h)+12%+19%-11%-3%
"],"adverse_reactions_table":["
Table 1 Incidence of Adverse Events Reported by ≥2% of Adult and Adolescent Allergic Rhinitis Patients Receiving Desloratadine Tablets
Adverse EventDesloratadine Tablets 5 mg (n=1655) Placebo (n=1652)
Infections and Infestations Pharyngitis 4.1%2.0%
Nervous System Disorders Somnolence2.1%1.8%
Gastrointestinal Disorders Dry Mouth 3.0%1.9%
Musculoskeletal and Connective Tissue Disorders Myalgia2.1%1.8%
Reproductive System and Breast Disorders Dysmenorrhea2.1%1.6%
General Disorders and Administration Site Conditions Fatigue2.1%1.2%
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). 17.1 Information for Patients • Patients should be instructed to use Desloratadine Tablets as directed. • As there are no food effects on bioavailability, patients can be instructed that Desloratadine Tablets may be taken without regard to meals. • Patients should be advised not to increase the dose or dosing frequency as studies have not demonstrated increased effectiveness at higher doses and somnolence may occur."],"spl_unclassified_section":["Manufactured by Belcher Pharmaceuticals, LLC. 6911 Bryan Dairy Road, Suite 210 Largo, FL 33777 Manufactured for: Virtus Pharmaceuticals, LLC Langhorne, PA 19047 1-888-848-3593 MADE IN USA Rev. 10/2020 L05I-VIR"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Desloratadine Tablets may be taken without regard to meals. Dosage (by age): Adults and Adolescents 12 Years of Age and Over: • Desloratadine Tablets - one 5 mg tablet once daily ( 2 ) 2.1 Adults and Adolescents 12 Years of Age and Over The recommended dose of Desloratadine Tablets is one 5-mg tablet once daily. 2.5 Adults with Hepatic or Renal Impairment In adult patients with liver or renal impairment, a starting dose of one 5 mg tablet every other day is recommended based on pharmacokinetic data. Dosing recommendation for children with liver or renal impairment cannot be made due to lack of data [ see Clinical Pharmacology (12.3) ]."],"drug_abuse_and_dependence":["9 DRUG ABUSE AND DEPENDENCE There is no information to indicate that abuse or dependency occurs with Desloratadine Tablets."],"spl_product_data_elements":["Desloratadine Desloratadine DESLORATADINE DESLORATADINE MICROCRYSTALLINE CELLULOSE CROSCARMELLOSE SODIUM TALC ZINC STEARATE FD&C BLUE NO. 2 STARCH, CORN light blue 5"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Desloratadine Tablets are light blue round tablets debossed with \"5\" containing 5 mg desloratadine. • Desloratadine Tablets - 5 mg ( 3 )"],"spl_patient_package_insert":["PATIENT INFORMATION Desloratadine Tablets Read the Patient Information that comes with Desloratadine Tablets before you start taking it and each time you get a refill. There may be new information. This leaflet is a summary of the information for patients. Your doctor or pharmacist can give you additional information. This leaflet does not take the place of talking to your doctor about your medical condition or treatment. What are Desloratadine Tablets? Desloratadine Tablets are a prescription medicine that contains the medicine desloratadine (an antihistamine). Desloratadine Tablets are used to help control the symptoms of: • seasonal allergic rhinitis (sneezing, stuffy nose, runny nose and itching of the nose) in people 12 years of age and older. • perennial allergic rhinitis (sneezing, stuffy nose, runny nose and itching of the nose) in people 12 years of age and older. • chronic idiopathic urticaria (long-term itching) and to reduce the number and size of hives in people 12 years of age and older. Desloratadine Tablets, 5 mg is not for children younger than 12 years of age. Who should not take Desloratadine Tablets? Do not take Desloratadine Tablets if you: • are allergic to desloratadine or any of the ingredients in Desloratadine Tablets. See the end of this leaflet for a complete list of ingredients. • are allergic to loratadine (Alavert, Claritin). Talk to your doctor before taking this medicine if you have any questions about whether or not to take this medicine. What should I tell my doctor before taking Desloratadine Tablets? Before you take Desloratadine Tablets, tell your doctor if you: • have liver or kidney problems. • have any other medical conditions. • are pregnant or plan to become pregnant. It is not known if Desloratadine will harm your unborn baby. Talk to your doctor if you are pregnant or plan to become pregnant. • are breast-feeding or plan to breast-feed. Desloratadine can pass into your breast milk. Talk to your doctor about the best way to feed your baby if you take Desloratadine. Tell your doctor about all the medicines you take, including prescription and non-prescription medicines, vitamins and herbal supplements. Desloratadine may affect the way other medicines work, and other medicines may affect how Desloratadine works. Especially tell your doctor if you take: • ketoconazole (Nizoral) • erythromycin (Ery-tab, Eryc, PCE) • azithromycin (Zithromax, Zmax) • antihistamines • fluoxetine (Prozac) • cimetidine (Tagamet) Know the medicines you take. Keep a list of your medicines and show it to your doctor and pharmacist when you get a new medicine. How should I take Desloratadine Tablets? • Take Desloratadine Tablets exactly as your doctor tells you to take it. • Do not change your dose of Desloratadine Tablets or take more often than prescribed. • Desloratadine Tablets can be taken with or without food. • If you take too many Desloratadine Tablets, call your doctor or get medical attention right away. What are the possible side effects of Desloratadine Tablets? Desloratadine Tablets may cause serious side effects, including: • Allergic reactions. Stop taking Desloratadine Tablets and call your doctor right away or get emergency help if you have any of these symptoms: o rash o itching o hives o swelling of your lips, tongue, face, and throat o shortness of breath or trouble breathing The most common side effects of Desloratadine Tablets in adults and children 12 years of age and older with allergic rhinitis include: • sore throat • dry mouth • muscle pain • tiredness • sleepiness • menstrual pain Increased sleepiness or tiredness can happen if you take more Desloratadine Tablets than your doctor prescribed to you. Tell your doctor if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of Desloratadine Tablets. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to Virtus Pharmaceuticals, LLC at 1-888-848-3593 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. How should I store Desloratadine Tablets? • Store Desloratadine Tablets between 59°F to 86°F (15°C to 30°C). • Desloratadine Tablets are sensitive to heat. Do not store above 86°F (30°C). • Protect Desloratadine Tablets from moisture. Keep Desloratadine Tablets , and all medicines out of the reach of children. General information about Desloratadine Tablets Medicines are sometimes prescribed for purposes other than those listed in a patient information leaflet. Do not use Desloratadine Tablets for a condition for which it was not prescribed. Do not give Desloratadine Tablets to other people, even if they have the same condition you have. It may harm them. This Patient Information leaflet summarizes the most important information about Desloratadine Tablets. If you would like more information, talk with your doctor. You can ask your pharmacist or doctor for information about Desloratadine Tablets that is written for health professionals. What are the ingredients in Desloratadine Tablets? Active ingredient: Desloratadine Inactive ingredients in Desloratadine Tablets: microcrystalline cellulose NF, pregelatinized starch NF, croscarmellose sodium NF, talc USP, zinc stearate, USP and FD&C Blue #2 HT 11-14%. Manufactured for: Virtus Pharmaceuticals, LLC Langhorne, PA 19047 1-888-848-3593 MADE IN USA Rev. 10/2020 R-2010"],"clinical_pharmacology_table":["
Table 2 Changes in Desloratadine and 3-Hydroxydesloratadine Pharmacokinetics in Healthy Male and Female Volunteers
Desloratadine3-Hydroxydesloratadine
CmaxAUC0-24 hrsCmaxAUC0-24 hrs
Erythromycin (500 mg Q8h)+24%+14%+43%+40%
Ketoconazole (200 mg Q12h)+45%+39%+43%+72%
Azithromycin (500 mg day 1, 250 mg QD × 4 days)+15%+5%+15%+4%
Fluoxetine (20 mg QD)+15%+0%+17%+13%
Cimetidine (600 mg Q12h)+12%+19%-11%-3%
"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS • Renal impairment: dosage adjustment is recommended ( 2.5 , 8.6 , 12.3 ) • Hepatic impairment: dosage adjustment is recommended ( 2.5 , 8.7 , 12.3 ) 8.1 Pregnancy Risk Summary The limited available data with Desloratadine in pregnant women are not sufficient to inform a drug-associated risk for major birth defects and miscarriage. There are no adequate and well-controlled studies in pregnant women. Desloratadine given during organogenesis to pregnant rats was not teratogenic at the summed area under the concentration-time curve (AUC)-based exposures of desloratadine and its metabolite approximately 320 times that at the recommended human daily oral dose (RHD) of 5 mg/day. Desloratadine given during organogenesis to pregnant rabbits was not teratogenic at the AUC-based exposures of desloratadine approximately 230 times that at the RHD. Desloratadine given to pregnant rats during organogenesis through lactation resulted in reduced body weight and slow righting reflex of F 1 pups at the summed AUC-based exposures of desloratadine and its metabolite approximately 70 times or greater than that at the RHD [ see Data ]. The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data Desloratadine was given orally during organogenesis to pregnant rats at doses of 6, 24 and 48 mg/kg/day (approximately 50, 200 and 320 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). No fetal malformations were present. Reduced fetal weights and skeletal variations noted at doses of 24 and 48 mg/kg/day were likely secondary to the maternal toxicities of reduced body weight gain and food consumption observed at the same doses. Desloratadine was also given orally during organogenesis to pregnant rabbits at doses of 15, 30 and 60 mg/kg/day (approximately 30, 70 and 230 times the AUC-based exposure of desloratadine at the RHD). No adverse effects to the fetus were noted. Reduced maternal body weight gain was noted in rabbits at 60 mg/kg/day. In a peri- and post-natal development study, desloratadine was given to rats orally during the perinatal (Gestation Day 6) through lactation periods (Postpartum Day 21) at doses of 3, 9 and 18 mg/kg/day. Reduced body weight and slow righting reflex were reported in F 1 pups at doses of 9 mg/kg/day or greater (approximately 70 times or greater than the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Desloratadine had no effect on F 1 pup development at 3 mg/kg/day (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Maternal toxicities including reduced body weight gain and food consumption were noted at 18 mg/kg/day for F 0 dams. F 1 offspring were subsequently mated and there was no developmental toxicity for F 2 pups observed. 8.2 Lactation Risk Summary Desloratadine passes into breast milk. There are not sufficient data on the effects of desloratadine on the breastfed infant or the effects of desloratadine on milk production. The decision should be made whether to discontinue nursing or to discontinue desloratadine, taking into account the developmental and health benefits of breastfeeding, the nursing mother's clinical need, and any potential adverse effects on the breastfed infant from desloratadine or from the underlying maternal condition. 8.3 Females and Males of Reproductive Potential Infertility There are no data available on human infertility associated with desloratadine. There were no clinically relevant effects of desloratadine on female fertility in rats. A male specific decrease in fertility occurred at an oral desloratadine dose of 12 mg/kg or greater in rats (approximately 65 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Male fertility was unaffected at a desloratadine dose of 3 mg/kg (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). [ See Nonclinical Toxicology (13.1) .] 8.4 Pediatric Use The recommended dose of Desloratadine Oral Solution in the pediatric population is based on cross-study comparison of the plasma concentration of Desloratadine in adults and pediatric subjects. The safety of Desloratadine Oral Solution has been established in 246 pediatric subjects aged 6 months to 11 years in three placebo-controlled clinical studies. Since the course of seasonal and perennial allergic rhinitis and chronic idiopathic urticaria and the effects of Desloratadine are sufficiently similar in the pediatric and adult populations, it allows extrapolation from the adult efficacy data to pediatric patients. The effectiveness of Desloratadine Oral Solution in these age groups is supported by evidence from adequate and well-controlled studies of Desloratadine Tablets in adults. The safety and effectiveness of Desloratadine Tablets or Desloratadine Oral Solution have not been demonstrated in pediatric patients less than 6 months of age. [ See Clinical Pharmacology (12.3) . ] 8.5 Geriatric Use Clinical studies of desloratadine did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. [ See Clinical Pharmacology (12.3) . ] 8.6 Renal Impairment Dosage adjustment for patients with renal impairment is recommended [ see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ]. 8.7 Hepatic Impairment Dosage adjustment for patients with hepatic impairment is recommended [ see Dosage and Administration (2.5) and Clinical Pharmacology (12.3) ]."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 5 mg Tablet Bottle Label Rx only NDC: 69543- 107 -10 Desloratadine TABLETS 5 mg 100 Tablets VIRTUS ® PHARMACEUTICALS 5 mg Tablet Bottle Label, 100-count"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity Studies The carcinogenic potential of desloratadine was assessed using a loratadine study in rats and a desloratadine study in mice. In a 2-year study in rats, loratadine was administered in the diet at doses up to 25 mg/kg/day (approximately 45 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD). A significantly higher incidence of hepatocellular tumors (combined adenomas and carcinomas) was observed in males given 10 mg/kg/day of loratadine (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD) and in males and females given 25 mg/kg/day of loratadine. The clinical significance of these findings during long-term use of desloratadine is not known. In a 2-year dietary study in mice, males and females given up to 16 mg/kg/day and 32 mg/kg/day desloratadine, respectively (approximately 30 and 70 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD, respectively), did not show significant increases in the incidence of any tumors. Genotoxicity Studies In genotoxicity studies with desloratadine, there was no evidence of genotoxic potential in a reverse mutation assay ( Salmonella/E. coli mammalian microsome bacterial mutagenicity assay) or in 2 assays for chromosomal aberrations (human peripheral blood lymphocyte clastogenicity assay and mouse bone marrow micronucleus assay). Impairment of Fertility In a female fertility study, desloratadine was given to female rats orally 14 days prior to and throughout mating until Gestation Day 7 at doses of 6, 12 and 24 mg/kg/day. An increase in preimplantation loss and a decrease in number of implantations and fetuses noted at 24 mg/kg (approximately 200 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD) was likely due to maternal toxicities including reduced body weight gain and food consumption. In a male fertility study in rats, desloratadine was given orally to male rats for 70 days prior to mating and throughout the mating period (total dosing period 106-108 days) at doses of 3, 12 and 40 mg/kg/day. Reduced body weight gain, food consumption, and absolute organ weights of testes, epididymis, and cauda epididymis were noted at 40 mg/kg/day. A male-specific decrease in fertility, demonstrated by reduced female conception rates, decreased sperm numbers and motility, and histopathologic changes in testes and epididymis, occurred at a dose of 12 mg/kg or greater (approximately 65 times or greater than the summed AUC-based exposure of desloratadine and its metabolite at the RHD). Desloratadine had no effect on male fertility in rats at 3 mg/kg/day (approximately 10 times the summed AUC-based exposure of desloratadine and its metabolite at the RHD)."]},"tags":[],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"607 reports"},{"date":"","signal":"FATIGUE","source":"FDA FAERS","actionTaken":"603 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"586 reports"},{"date":"","signal":"DYSPNOEA","source":"FDA FAERS","actionTaken":"535 reports"},{"date":"","signal":"HEADACHE","source":"FDA FAERS","actionTaken":"466 reports"},{"date":"","signal":"DIARRHOEA","source":"FDA FAERS","actionTaken":"450 reports"},{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"443 reports"},{"date":"","signal":"PRURITUS","source":"FDA FAERS","actionTaken":"425 reports"},{"date":"","signal":"VOMITING","source":"FDA FAERS","actionTaken":"403 reports"},{"date":"","signal":"RASH","source":"FDA FAERS","actionTaken":"376 reports"}],"drugInteractions":[],"commonSideEffects":[{"effect":"Upper respiratory tract infections","drugRate":"21.2%","severity":"common","organSystem":""},{"effect":"Diarrhea","drugRate":"19.7%","severity":"common","organSystem":""},{"effect":"Fever","drugRate":"16.9%","severity":"common","organSystem":""},{"effect":"Coughing","drugRate":"10.8%","severity":"common","organSystem":""},{"effect":"Irritability","drugRate":"12.1%","severity":"common","organSystem":""},{"effect":"Somnolence","drugRate":"9.1%","severity":"common","organSystem":""},{"effect":"Bronchitis","drugRate":"6.1%","severity":"common","organSystem":""},{"effect":"Vomiting","drugRate":"6.1%","severity":"common","organSystem":""},{"effect":"Urinary tract infection","drugRate":"5.5%","severity":"common","organSystem":""},{"effect":"Otitis media","drugRate":"6.1%","severity":"common","organSystem":""},{"effect":"Anorexia","drugRate":"4.5%","severity":"common","organSystem":""},{"effect":"Pharyngitis","drugRate":"4.5%","severity":"common","organSystem":""},{"effect":"Insomnia","drugRate":"4.5%","severity":"common","organSystem":""},{"effect":"Rhinorrhea","drugRate":"4.5%","severity":"common","organSystem":""},{"effect":"Appetite increased","drugRate":"3.1%","severity":"common","organSystem":""},{"effect":"Emotional lability","drugRate":"3.1%","severity":"common","organSystem":""},{"effect":"Epistaxis","drugRate":"3.1%","severity":"common","organSystem":""},{"effect":"Parasitic infection","drugRate":"3.1%","severity":"common","organSystem":""},{"effect":"Rash maculopapular","drugRate":"3.1%","severity":"common","organSystem":""},{"effect":"Erythema","drugRate":"3%","severity":"common","organSystem":""}],"contraindications":["Angle-closure glaucoma","Benign prostatic hyperplasia","Coronary arteriosclerosis","Diabetes mellitus","Disease of liver","Hypertensive disorder","Hypertensive urgency","Hyperthyroidism","Kidney disease","Retention of urine"],"specialPopulations":{},"discontinuationRates":[],"seriousAdverseEvents":[]},"status":"approved","trials":["NCT05232825","NCT00816972","NCT00783146","NCT00783133","NCT00761527","NCT01108783","NCT04399525","NCT01601522","NCT00636870","NCT00862225","NCT00598611","NCT01400828","NCT00405964","NCT06806826","NCT06272409","NCT06268470","NCT00794248","NCT00424580","NCT07109817","NCT01918033","NCT01506050","NCT00805584","NCT00783211","NCT00704769","NCT02904304","NCT00794378","NCT05446480","NCT00794768","NCT07333716","NCT00789152","NCT00866788","NCT05214911","NCT01720485","NCT01314352","NCT00637585","NCT02507635","NCT01740284","NCT06217367","NCT00795522","NCT01916967","NCT01314339","NCT00751166","NCT00805324","NCT02646020","NCT00783354","NCT00751218","NCT00794794","NCT00724698","NCT00600847","NCT00795158"],"aliases":["Clarinex","Aerius"],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$0.3546/EA","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$129","description":"DESLORATADINE 5 MG TABLET","retrievedDate":"2026-04-07"}],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=desloratadine","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:33:35.950954+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:33:42.594318+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T02:33:34.578305+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=desloratadine","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:33:43.435503+00:00"},"mechanism.drugClass":{"url":"https://api.fda.gov/drug/label.json","method":"deterministic","source":"FDA Label (EPC)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:33:33.208129+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:33:33.208175+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:33:33.208188+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T02:33:45.133720+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Histamine H1 receptor antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:33:44.000780+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1172/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:33:43.896784+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"ANDA078355","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:33:33.208447+00:00"}},"allNames":"clarinex","offLabel":[],"timeline":[],"aiSummary":"Desloratadine (Clarinex/Aerius) is the active metabolite of loratadine, approved in 2001. More potent with additional anti-inflammatory properties. Available generically in many markets.","brandName":"Clarinex","companyId":"unknown","ecosystem":[],"mechanism":{"target":"5-hydroxytryptamine receptor 6, Histamine H4 receptor, Multidrug resistance protein 1","novelty":"","modality":"Small molecule","drugClass":"Histamine-1 Receptor Antagonist [EPC]","explanation":"Desloratadine is the active metabolite of loratadine, approximately 10-20x more potent at the H1 receptor. It also has anti-inflammatory properties beyond simple H1 blockade, inhibiting cytokine and chemokine release from mast cells and basophils.","oneSentence":"Active metabolite of loratadine with higher potency at H1 receptors and additional anti-inflammatory properties.","technicalDetail":""},"commercial":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:33:50.661116+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"companyName":"Generic (originally Schering-Plough/MSD)","competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"genericName":"desloratadine","indications":{"approved":[{"name":"Allergic conjunctivitis","diseaseId":"allergic-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic rhinitis","diseaseId":"allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Allergic urticaria","diseaseId":"allergic-urticaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chronic idiopathic urticaria","diseaseId":"chronic-idiopathic-urticaria","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Common cold","diseaseId":"common-cold","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal congestion","diseaseId":"nasal-congestion","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Nasal discharge","diseaseId":"nasal-discharge","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Seasonal allergic rhinitis","diseaseId":"seasonal-allergic-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Sneezing","diseaseId":"sneezing","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Vasomotor rhinitis","diseaseId":"vasomotor-rhinitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05232825","phase":"Phase 3","title":"A Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Scleros","status":"COMPLETED","sponsor":"Hoffmann-La Roche","isPivotal":true,"enrollment":236,"indication":"Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis","completionDate":"2025-06-06"},{"nctId":"NCT00816972","phase":"Phase 2","title":"Pilot Efficacy and Safety Field Trial of Desloratadine Administered Concomitantly With Oxybutynin, in Subjects With Seasonal Allergic Rhinitis and Post-Nasal Drip","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":540,"indication":"Post-nasal Drip, Seasonal Allergic Rhinitis","completionDate":"2005-06"},{"nctId":"NCT00783146","phase":"Phase 4","title":"A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":728,"indication":"Seasonal Allergic Rhinitis","completionDate":"2004-10-01"},{"nctId":"NCT00783133","phase":"Phase 4","title":"Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":131,"indication":"Seasonal Allergic Rhinitis","completionDate":"2003-06-01"},{"nctId":"NCT00761527","phase":"N/A","title":"Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Syrup Among Filipino Pediatric Patients","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":2980,"indication":"Rhinitis, Allergic, Seasonal, Rhinitis, Allergic, Perennial","completionDate":"2010-05"},{"nctId":"NCT01108783","phase":"Phase 3","title":"Double-blind, Randomized, Placebo-controlled, Phase III Study Comparing the Efficacy and Safety of Bilastine 20 mg Once Daily and Desloratadine 5 mg for the Treatment of Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Faes Farma, S.A.","isPivotal":true,"enrollment":720,"indication":"Seasonal Allergic Rhinitis","completionDate":"2004-02"},{"nctId":"NCT04399525","phase":"NA","title":"Influence of H1-antihistamines on the Dermal Blood Flow Response After a Histamine Skin Prick as Well as After the Topical Application of Cinnamaldehyde and Capsaicin","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","isPivotal":false,"enrollment":12,"indication":"Pruritus","completionDate":"2020-03-12"},{"nctId":"NCT01601522","phase":"Phase 2","title":"Peanut Allergy Oral Immunotherapy Desensitization","status":"COMPLETED","sponsor":"Hamilton Health Sciences Corporation","isPivotal":false,"enrollment":43,"indication":"Peanut Allergy","completionDate":"2021-09"},{"nctId":"NCT00636870","phase":"Phase 4","title":"A Randomized, Double-blind, Repeat-dose, Crossover Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Desloratadine (Clarinex®) Compared to Fexofenadine (Allegra®) in Healthy Adults W","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":220,"indication":"Allergic Rhinitis","completionDate":"2004-01"},{"nctId":"NCT00862225","phase":"Phase 2","title":"Randomized, Double-blind Prospective Clinical Study to Examine the Mechanism of Action of IG-RD-001 (Ze-339) Compared to Desloratadine and Placebo in Patients With Seasonal Allergic Rhinitis Who Are S","status":"COMPLETED","sponsor":"Max Zeller Soehne AG","isPivotal":false,"enrollment":18,"indication":"Seasonal Allergic Rhinitis","completionDate":"2008-12"},{"nctId":"NCT00598611","phase":"Phase 3","title":"An Exploratory Phase III, Randomised, Double-blind, Therapeutic Single Dose-related Effect, Parallel Group Study to Assess and Compare the Effects of 5 mg vs. 20 mg Desloratadine on Skin Lesions in Pa","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","isPivotal":true,"enrollment":29,"indication":"Chronic Urticaria","completionDate":"2009-08"},{"nctId":"NCT01400828","phase":"Phase 3","title":"Randomized, Double-blind, Placebo/Active-controlled, Multi-center Clinical Trial to Investigate the Safety/Tolerability and Efficacy of Bilastine 20mg After 14-day Oral Administration in Patients With","status":"COMPLETED","sponsor":"Yuhan Corporation","isPivotal":true,"enrollment":239,"indication":"Seasonal Allergic Rhinitis","completionDate":"2014-05"},{"nctId":"NCT00405964","phase":"Phase 3","title":"Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter/Multinational, Efficacy and Safety Study of Desloratadine 5 mg in the Treatment of Subjects With Allergic Rhinitis Who Meet th","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":716,"indication":"Allergic Rhinitis","completionDate":"2008-04"},{"nctId":"NCT06806826","phase":"Phase 4","title":"Evaluatıon of the Effectıveness of Omalızumab Treatment In Patıents Wıth Allergıc Rhınıtıs","status":"COMPLETED","sponsor":"Yuzuncu Yil University","isPivotal":false,"enrollment":50,"indication":"Allergic Rhinitis","completionDate":"2020-03-01"},{"nctId":"NCT06272409","phase":"Phase 3","title":"Phase III, Multicenter, Double-blind, Planned, Parallel Clinical Trial to Evaluate the Efficacy and Safety of DEP114 in the Treatment of Moderate to Severe Persistent Allergic Rhinitis in Children Age","status":"NOT_YET_RECRUITING","sponsor":"EMS","isPivotal":true,"enrollment":318,"indication":"Allergic Rhinitis","completionDate":"2027-04-15"},{"nctId":"NCT06268470","phase":"Phase 2","title":"Efficacy of Antiplatelet Therapy for the Treatment of Chronic Recalcitrant Urticaria","status":"UNKNOWN","sponsor":"Chulalongkorn University","isPivotal":false,"enrollment":12,"indication":"Chronic Urticaria","completionDate":"2024-05-01"},{"nctId":"NCT00794248","phase":"Phase 4","title":"Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":122,"indication":"Seasonal Allergic Rhinitis","completionDate":"2003-05"},{"nctId":"NCT00424580","phase":"NA","title":"Airway Responses to Montelukast and Desloratadine.","status":"COMPLETED","sponsor":"University of Saskatchewan","isPivotal":false,"enrollment":12,"indication":"Asthma","completionDate":"2007-08"},{"nctId":"NCT07109817","phase":"Phase 2","title":"Desloratadine to Prevent Taxane-induced Peripheral Neuropathy in Patients With Breast Cancer (DETOXp)","status":"NOT_YET_RECRUITING","sponsor":"Montefiore Medical Center","isPivotal":false,"enrollment":116,"indication":"Breast Cancer, Peripheral Neuropathy","completionDate":"2030-06"},{"nctId":"NCT01918033","phase":"Phase 3","title":"A Phase III, Multi-Center, Randomized, Parallel-Group, Placebo-Controlled and Double- Blind Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Perennial Allergic Rhinitis","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":608,"indication":"Perennial Allergic Rhinitis","completionDate":"2014-01-26"},{"nctId":"NCT01506050","phase":"Phase 1","title":"Randomized, Single Dose, 2-Way Crossover, Relative Bioavailability Study of Desloratadine Orally Disintegrating Tablet Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":35,"indication":"Healthy","completionDate":"2006-02"},{"nctId":"NCT00805584","phase":"Phase 4","title":"A Multi-center, Open-label, Non-comparative Study of the Relief of Nasal Symptoms and Tolerability in Subjects With Seasonal Allergic Rhinitis (SAR) Treated With Aerius.","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":311,"indication":"Rhinitis, Allergic, Seasonal","completionDate":"2003-06"},{"nctId":"NCT00783211","phase":"Phase 4","title":"A Placebo Controlled Study of the Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. in the Treatment of Subjects With Symptomatic Seasonal Allergic Rhinitis (SAR)","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":722,"indication":"Seasonal Allergic Rhinitis","completionDate":"2004-10-01"},{"nctId":"NCT00704769","phase":"N/A","title":"Observational Study Evaluating the Safety and Efficacy of Desloratadine Syrup for Perennial Allergic Rhinitis in Indonesian Pediatric Patients","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":591,"indication":"Rhinitis","completionDate":"2007-12"},{"nctId":"NCT02904304","phase":"Phase 3","title":"National Clinical Trial,Phase III, Multicenter, Randomized, Prospective, Double-blind, Parallel, Placebo-controlled, to Evaluate the Efficacy, Safety and Superiority of Decongex Gripe in the Treatment","status":"SUSPENDED","sponsor":"Ache Laboratorios Farmaceuticos S.A.","isPivotal":true,"enrollment":150,"indication":"Cold","completionDate":"2021-09"},{"nctId":"NCT00794378","phase":"Phase 3","title":"A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":202,"indication":"Allergic Rhinitis","completionDate":"2004-11"},{"nctId":"NCT05446480","phase":"NA","title":"Potential Off-label Use of Desloratadine to Mitigate Inflammation Caused by PPE-induced Heat Stress","status":"UNKNOWN","sponsor":"University of Victoria","isPivotal":false,"enrollment":12,"indication":"Heat Stress, Exertional, Inflammatory Response","completionDate":"2023-08"},{"nctId":"NCT00794768","phase":"Phase 4","title":"Preference Evaluation of Clarinex Tablets vs. Allegra Tablets in Subjects With Symptomatic Seasonal Allergic Rhinitis","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":118,"indication":"Seasonal Allergic Rhinitis","completionDate":"2003-07"},{"nctId":"NCT07333716","phase":"Phase 2","title":"Efficacy and Safety of Desloratadine as Adjuvant Therapy in Patients With Ulcerative Colitis","status":"RECRUITING","sponsor":"Tanta University","isPivotal":false,"enrollment":44,"indication":"Ulcerative Colitis (UC), Ulcerative Colitis","completionDate":"2027-03"},{"nctId":"NCT00789152","phase":"Phase 3","title":"The Effects of Desloratadine and Levocetirizine on Nasal Obstruction in Subjects With Induced Allergic Rhinitis in the VCC Assessed Clinically and With Nasal Rhinomanometry and Nasal Flowmetry","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":81,"indication":"Allergic Rhinitis","completionDate":"2004-05-01"},{"nctId":"NCT00866788","phase":"Phase 2","title":"A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study of Xolair (Omalizumab) in Patients With Chronic Idiopathic Urticaria (CIU) Who Remain Symptomatic With Antihist","status":"COMPLETED","sponsor":"Genentech, Inc.","isPivotal":false,"enrollment":90,"indication":"Chronic Idiopathic Urticaria","completionDate":"2010-01"},{"nctId":"NCT05214911","phase":"Phase 3","title":"Multicenter,Randomized, Parallel,Double-blind, Comparative Study of the Superiority of the Desloratadine 0.5mg/mL and Prednisolone 4 mg/mL Versus Desloratadine 0.5mg/mL in the Treatment of Persistent ","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","isPivotal":true,"enrollment":262,"indication":"Allergic Rhinitis","completionDate":"2025-03-23"},{"nctId":"NCT01720485","phase":"Phase 3","title":"A Double-blind,Double Dummy, Randomized, Multicenter Parallel-group Study on Efficacy of Desloratadine and Prednisolone Association Compared to Dexchlorpheniramine and Betamethasone Association in Adu","status":"UNKNOWN","sponsor":"EMS","isPivotal":true,"enrollment":234,"indication":"Allergic Rhinitis","completionDate":"2014-03"},{"nctId":"NCT01314352","phase":"Phase 1","title":"A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fed Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":28,"indication":"Fed","completionDate":"2006-03"},{"nctId":"NCT00637585","phase":"Phase 4","title":"A Comparison of Fexofenadine HCl 180 mg, Desloratadine 5 mg and Placebo in Suppression of Wheal and Flare Induced by Histamine","status":"COMPLETED","sponsor":"Sanofi","isPivotal":false,"enrollment":42,"indication":"Allergic Rhinitis","completionDate":"2003-07"},{"nctId":"NCT02507635","phase":"Phase 4","title":"In Vivo Anti-inflammatory Effect of H1 Antihistamines in Allergic Rhinitis","status":"COMPLETED","sponsor":"Iuliu Hatieganu University of Medicine and Pharmacy","isPivotal":false,"enrollment":115,"indication":"Allergic Rhinitis","completionDate":"2013-05"},{"nctId":"NCT01740284","phase":"Phase 3","title":"A Phase III Trial Evaluating Tolerability of Grazax Treatment in Combination With Antihistamine in Subjects With Seasonal Grass Pollen Induced Rhinoconjunctivitis","status":"COMPLETED","sponsor":"ALK-Abelló A/S","isPivotal":true,"enrollment":46,"indication":"Allergic Rhinoconjunctivitis","completionDate":"2009-01"},{"nctId":"NCT06217367","phase":"Phase 4","title":"Do Common Over-the-counter Antihistamine Medications Modify Thermoregulatory Responses During Passive Heat Stress?","status":"UNKNOWN","sponsor":"Lakehead University","isPivotal":false,"enrollment":16,"indication":"Heat Illness, Allergic Rhinitis","completionDate":"2024-06"},{"nctId":"NCT00795522","phase":"Phase 4","title":"An Open-Label Study of the Effects of Desloratadine (Aerius.) Treatment on the Quality of Life of Patients With Chronic Idiopathic Urticaria","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":51,"indication":"Urticaria","completionDate":"2005-03"},{"nctId":"NCT01916967","phase":"Phase 3","title":"A Phase III Multicentre, Parallel-group, Randomized, Placebo-controlled, Double-blind Clinical Trial to Study the Efficacy and Safety of MK-4117 in Japanese Subjects With Chronic Urticaria.","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":239,"indication":"Urticaria","completionDate":"2014-03-13"},{"nctId":"NCT01314339","phase":"Phase 1","title":"A Randomized, Single-Dose, Two-Way Crossover Relative Bioavailability Study of Desloratadine 5 mg Tablet in Healthy Subjects Under Fasting Conditions","status":"COMPLETED","sponsor":"Dr. Reddy's Laboratories Limited","isPivotal":false,"enrollment":28,"indication":"Fasting","completionDate":"2006-02"},{"nctId":"NCT00751166","phase":"Phase 4","title":"A Comparative Double-blind, Double-dummy Study of Desloratadine (DL) 5 mg Once Daily, Cetirizine 10 mg Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU)","status":"TERMINATED","sponsor":"Organon and Co","isPivotal":false,"enrollment":149,"indication":"Urticaria","completionDate":"2005-05-01"},{"nctId":"NCT00805324","phase":"Phase 3","title":"Evaluation of the Efficacy and Safety of Desloratadine Syrup in Children Suffering From Seasonal Allergic Rhinitis With or Without Intermittent Asthma","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":54,"indication":"Rhinitis, Allergic, Seasonal, Asthma","completionDate":"2003-08"},{"nctId":"NCT02646020","phase":"Phase 2","title":"Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded","status":"COMPLETED","sponsor":"Sun Yat-sen University","isPivotal":false,"enrollment":138,"indication":"Non-small Cell Lung Cancer","completionDate":"2020-12-01"},{"nctId":"NCT00783354","phase":"Phase 4","title":"A Pilot, Multicenter, Double-blind Randomized Study for Comparison of Aerius® \"Continuous Treatment\" Versus Aerius® \"PRN Regimen\" on Chronic Idiopathic Urticaria Patient Quality of Life","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":129,"indication":"Urticaria, Chronic Idiopathic Urticaria","completionDate":"2004-04-01"},{"nctId":"NCT00751218","phase":"Phase 4","title":"A Comparative Double-Blind, Double- Dummy Study of Desloratadine (DL) 5 MG Once Daily, Cetirizine 10 MG Once Daily, and Placebo Once Daily in Patients With Chronic Idiopathic Urticaria (CIU)","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":174,"indication":"Urticaria","completionDate":"2005-05-24"},{"nctId":"NCT00794794","phase":"Phase 3","title":"A Single-Center, Pediatric, Comparative Taste Test of Desloratadine and Cetirizine Antihistamine Syrup Medications","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":204,"indication":"Allergic Rhinitis","completionDate":"2004-11"},{"nctId":"NCT00724698","phase":"N/A","title":"Post-marketing Surveillance of the Safety, Tolerability and Efficacy of Desloratadine Tablet Among Filipino Patients","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":false,"enrollment":3011,"indication":"Rhinitis, Urticaria","completionDate":"2007-12"},{"nctId":"NCT00600847","phase":"Phase 4","title":"An Exploratory Phase IV, Randomised, Double-Blind, Placebo Controlled Crossover Study to Compare the Effects of 5 mg vs. 20 mg Desloratadine on the Development of Experimentally Induced Urticaria Lesi","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","isPivotal":false,"enrollment":33,"indication":"Acquired Cold Urticaria","completionDate":""},{"nctId":"NCT00795158","phase":"Phase 3","title":"An Open-Label Study of the Effects of Desloratadine Treatment on the Quality of Life of Patients With Chronic Urticaria","status":"COMPLETED","sponsor":"Organon and Co","isPivotal":true,"enrollment":282,"indication":"Urticaria","completionDate":"2004-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"icon":"","route":"Oral","frequency":"Once daily","formulation":"Tablet, Orally disintegrating tablet, Oral syrup"},"crossReferences":{"chemblId":"CHEMBL1172"},"formularyStatus":[],"apiManufacturers":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":722,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"firstApprovalDate":"2001-12-21","companionDiagnostics":[],"firstApprovalCountry":"United States","genericManufacturerList":[],"modality":"Small molecule","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2006-12-14T00:00:00.000Z","mah":"ORGANON","brand_name_local":null,"application_number":"NDA021165"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-02-19T00:00:00.000Z","mah":"ORBION PHARMS","brand_name_local":null,"application_number":"ANDA078357"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2010-07-12T00:00:00.000Z","mah":"REDDYS","brand_name_local":null,"application_number":"ANDA078367"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2012-04-19T00:00:00.000Z","mah":"AJENAT PHARMS","brand_name_local":null,"application_number":"ANDA078355"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2015-10-16T00:00:00.000Z","mah":"ORGANON LLC","brand_name_local":null,"application_number":"NDA021313"},{"country_code":"NZ","regulator":"Medsafe","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"AT","regulator":"AGES","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"BE","regulator":"FAMHP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":"EMEA/H/C/000313"},{"country_code":"GB","regulator":"MHRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"BG","regulator":"BDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"HR","regulator":"HALMED","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"CY","regulator":"PHS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"CZ","regulator":"SUKL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"DK","regulator":"DKMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"EE","regulator":"SAM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"FI","regulator":"Fimea","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"FR","regulator":"ANSM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"DE","regulator":"BfArM","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"GR","regulator":"EOF","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"HU","regulator":"OGYEI","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"IE","regulator":"HPRA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"IT","regulator":"AIFA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"LV","regulator":"ZVA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"LT","regulator":"VVKT","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"LU","regulator":"MS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"MT","regulator":"MMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"NL","regulator":"MEB","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"PL","regulator":"URPL","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"PT","regulator":"Infarmed","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"RO","regulator":"ANMDMR","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"SK","regulator":"SIDC","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"SI","regulator":"JAZMP","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"ES","regulator":"AEMPS","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"SE","regulator":"MPA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"CH","regulator":"Swissmedic","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"NO","regulator":"NoMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null},{"country_code":"IS","regulator":"IMA","status":"approved","approval_date":null,"mah":null,"brand_name_local":"Aerius","application_number":null}],"trialStats":{"total":8,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:33:50.661116+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}